Alembic Pharmaceuticals

Alembic Pharmaceuticals has secured approval from the U.S. Food and Drug Administration (USFDA) for its Macitentan tablets, a key treatment for pulmonary arterial hypertension (PAH). This approval enables Alembic to market the drug in the highly regulated U.S. pharmaceutical market, marking a significant milestone in its international expansion strategy. Analysts note that entering the U.S. market not only diversifies revenue streams but also reinforces Alembic’s global credibility in specialty therapies.

Alembic Pharmaceuticals has received regulatory clearance from the U.S. Food and Drug Administration (USFDA) to commercialize a generic version of Carbamazepine Tablets USP, 200 mg in the American market. The product, a therapeutic equivalent to Novartis' Tegretol, is used primarily in the treatment of epilepsy and trigeminal neuralgia. With an estimated market size of USD 32 million as of December 2024, the approval strengthens Alembic’s presence in the U.S. generics segment.